MIRELLE

This brand name is authorized in Austria, Brazil, Estonia, Lithuania, South Africa.

Active ingredients

The drug MIRELLE contains a combination of these active pharmaceutical ingredients (APIs):

1	17 alpha-Ethinylestradiol UNII 423D2T571U - ETHINYL ESTRADIOL
	Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.
	Read more about 17 alpha-Ethinylestradiol
2	Gestodene UNII 1664P6E6MI - GESTODENE
	Read more about Gestodene

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
MIRELLE Film-coated tablet	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03AA10	Gestodene and ethinylestradiol	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AA Progestogens and estrogens, fixed combinations
Discover more medicines within G03AA10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	538912050012014
EE	Ravimiamet	1012149, 1093890
LT	Valstybinė vaistų kontrolės tarnyba	1007429
ZA	Health Products Regulatory Authority	33/18.8/0364